FindTrial
Sign In

NGFR-transduced Autologous T Lymphocytes

BIOLOGICAL2 trials

Sponsors

M.D. Anderson Cancer Center

Conditions

Metastatic MelanomaStage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7

Phase 1

Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
CompletedNCT01740557
M.D. Anderson Cancer CenterMetastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Start: 2015-01-28End: 2023-04-21Updated: 2024-10-08
Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma
Active, not recruitingNCT01955460
M.D. Anderson Cancer CenterMetastatic Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7 +3
Start: 2014-10-15End: 2027-10-30Target: 34Updated: 2026-04-15

Related Papers

340 TGFβDNRII genetically-engineered TIL: characterizing final drug product from a phase I clinical trial
Regular and Young Investigator Award Abstracts2023-10-31
CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling
Journal for ImmunoTherapy of Cancer2022-07-0138 citations
172 Overcoming immunosuppressive TGF-β signaling in human ovarian cancer-derived tumor infiltrating lymphocytes via non-viral CRISPR engineering
Regular and Young Investigator Award Abstracts2021-11-011 citations